ArticleAdvances in rheumatology (London, England)2025
A retrospective cohort study of 203 patients with Takayasu arteritis: experience from a Brazilian tertiary center.
Article in Advances in rheumatology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTakayasu arteritis (TAK) is a rare form of systemic vasculitis that primarily affects the aorta and its major branches. Despite several epidemiological studies on TAK, only a few descriptive studies have been conducted in our country, which motivated us to conduct this study.
methodsThis single-center retrospective cohort study included Brazilian patients with TAK who underwent follow-up at a tertiary outpatient clinic between January 2000 and June 2024. Patient data were extracted from electronic medical records using standardized and parameterized information.
resultsA total of 203 patients with TAK were included, with a predominance of Caucasians (83.7%) and females (79.8%). The median age at disease diagnosis was 28.0 (interquartile range: 20.0–38.0) years, and the median follow-up period was 122.0 (49.0-177.0) months. During the initial or follow-up period, 65.0% of patients used GC and 80.0% used IM/IB drugs. The three most common Hata classifications were V (46.8%), IV (23.2%), and I (22.7%). There was a high burden of cardiovascular risk factors, including hypertension (72.9%), dyslipidemia (59.1%), and renovascular hypertension (22.7%). When patients were analyzed according to age quartiles, those who were older at the time of analysis predominantly achieved sustained remission without the need for GC or IS therapy.
conclusionsThis is the largest cohort study to include Brazilian patients with TAK. Even with higher cardiovascular risk factors than in other series, we observed lower rates of ischemic or cardiovascular events. Moreover, disease activity and treatment patterns varied significantly according to patient age at the time of analysis, with older patients being less likely to require ongoing IS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.